(Approval lapsed) GlucaGen HypoKit glucagon 1mg powder and solvent for solution for injection (Switzerland)

Therapeutic: Treatment of severe hypoglycaemic reactions which may occur in the management of diabetic patients receiving insulin or oral hypoglycaemic agents. To prevent the occurrence of secondary hypoglycaemia, oral carbohydrate should be given to restore the hepatic glycogen when the patient has responded to the treatment. The mechanism and hence treatment of sulfonylurea-induced hypoglycaemia differs from that of severe insulin-induced hypoglycaemia in some important ways. Consciousness should preferably be restored by the administration of intravenous glucose. If glucagon is used due to the unavailability of intravenous glucose (e.g. before reaching a hospital) care should be taken to protect against secondary hypoglycaemia with constant monitoring of the patient's blood sugar level by medical personnel. Subsequent administration of intravenous glucose may be required.

Diagnostic: Motility inhibitor in examinations of the gastrointestinal tract in adults, e.g. double contrast radiography and endoscopy.